Johnson & Johnsonvs.Pfizer
JNJ vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 4.1× larger than Pfizer by market cap; Johnson & Johnson trades at the lower P/E (29.9 vs 35.2); year to date, Johnson & Johnson leads (+31.9% vs +12.3%).
Side by side
| JNJ | PFE | |
|---|---|---|
| Market cap | $630B | $152B |
| Price | $273.14 | $28.57 |
| Today | +0.0% | +2.1% |
| Return YTD | +31.9% | +12.3% |
| Return 1Y | +52.3% | +8.1% |
| P/E | 29.9 | 35.2 |
| P/S | 6.4 | 2.4 |
| P/B | 7.4 | 1.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.
Full JNJ profile →PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →More JNJ & PFE comparisons
Other head-to-heads in the Big pharma segment.